nodes	percent_of_prediction	percent_of_DWPC	metapath
Ezogabine—CYP2A6—Progesterone—uterine cancer	0.289	0.571	CbGbCtD
Ezogabine—UGT1A1—Etoposide—uterine cancer	0.218	0.43	CbGbCtD
Ezogabine—KCNQ5—Potassium Channels—ABCC9—uterine cancer	0.00605	0.0486	CbGpPWpGaD
Ezogabine—KCNQ4—Potassium Channels—ABCC9—uterine cancer	0.00605	0.0486	CbGpPWpGaD
Ezogabine—NAT2—renal system—uterine cancer	0.00509	0.167	CbGeAlD
Ezogabine—KCNQ5—female reproductive system—uterine cancer	0.00347	0.114	CbGeAlD
Ezogabine—UGT1A4—renal system—uterine cancer	0.00328	0.108	CbGeAlD
Ezogabine—KCNQ2—Potassium Channels—ABCC9—uterine cancer	0.00327	0.0263	CbGpPWpGaD
Ezogabine—KCNQ3—Potassium Channels—ABCC9—uterine cancer	0.00327	0.0263	CbGpPWpGaD
Ezogabine—KCNQ5—vagina—uterine cancer	0.00314	0.103	CbGeAlD
Ezogabine—KCNQ3—female reproductive system—uterine cancer	0.00278	0.0913	CbGeAlD
Ezogabine—UGT1A9—renal system—uterine cancer	0.00275	0.0902	CbGeAlD
Ezogabine—CYP2A6—Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis—NFE2L2—uterine cancer	0.00271	0.0217	CbGpPWpGaD
Ezogabine—KCNQ5—Neuronal System—ABCC9—uterine cancer	0.00264	0.0212	CbGpPWpGaD
Ezogabine—KCNQ4—Neuronal System—ABCC9—uterine cancer	0.00264	0.0212	CbGpPWpGaD
Ezogabine—UGT1A4—Aryl Hydrocarbon Receptor Pathway—NFE2L2—uterine cancer	0.00263	0.0211	CbGpPWpGaD
Ezogabine—KCNQ2—female reproductive system—uterine cancer	0.00256	0.0841	CbGeAlD
Ezogabine—Dysuria—Progesterone—uterine cancer	0.00239	0.00705	CcSEcCtD
Ezogabine—NAT2—Metapathway biotransformation—AKR1B10—uterine cancer	0.00237	0.019	CbGpPWpGaD
Ezogabine—KCNQ2—female gonad—uterine cancer	0.00233	0.0765	CbGeAlD
Ezogabine—Weight increased—Progesterone—uterine cancer	0.00232	0.00686	CcSEcCtD
Ezogabine—Influenza—Medroxyprogesterone Acetate—uterine cancer	0.00231	0.00683	CcSEcCtD
Ezogabine—Dysphagia—Medroxyprogesterone Acetate—uterine cancer	0.00231	0.00683	CcSEcCtD
Ezogabine—Skin discolouration—Etoposide—uterine cancer	0.0023	0.0068	CcSEcCtD
Ezogabine—Infestation NOS—Progesterone—uterine cancer	0.00227	0.00672	CcSEcCtD
Ezogabine—Infestation—Progesterone—uterine cancer	0.00227	0.00672	CcSEcCtD
Ezogabine—NAT2—Metapathway biotransformation—AKR1B1—uterine cancer	0.0022	0.0177	CbGpPWpGaD
Ezogabine—UGT1A3—Aryl Hydrocarbon Receptor Pathway—NFE2L2—uterine cancer	0.00218	0.0175	CbGpPWpGaD
Ezogabine—Dysuria—Medroxyprogesterone Acetate—uterine cancer	0.00216	0.00639	CcSEcCtD
Ezogabine—Hepatobiliary disease—Progesterone—uterine cancer	0.00215	0.00636	CcSEcCtD
Ezogabine—Weight increased—Medroxyprogesterone Acetate—uterine cancer	0.0021	0.00622	CcSEcCtD
Ezogabine—Infestation—Medroxyprogesterone Acetate—uterine cancer	0.00206	0.00609	CcSEcCtD
Ezogabine—Infestation NOS—Medroxyprogesterone Acetate—uterine cancer	0.00206	0.00609	CcSEcCtD
Ezogabine—KCNQ5—lymph node—uterine cancer	0.00203	0.0666	CbGeAlD
Ezogabine—Urinary tract disorder—Progesterone—uterine cancer	0.00202	0.00596	CcSEcCtD
Ezogabine—Oedema peripheral—Progesterone—uterine cancer	0.00201	0.00594	CcSEcCtD
Ezogabine—Urethral disorder—Progesterone—uterine cancer	0.002	0.00591	CcSEcCtD
Ezogabine—Visual impairment—Progesterone—uterine cancer	0.00197	0.00581	CcSEcCtD
Ezogabine—KCNQ2—Axon guidance—PLXNA3—uterine cancer	0.00196	0.0158	CbGpPWpGaD
Ezogabine—KCNQ3—Axon guidance—PLXNA3—uterine cancer	0.00196	0.0158	CbGpPWpGaD
Ezogabine—Hepatobiliary disease—Medroxyprogesterone Acetate—uterine cancer	0.00195	0.00576	CcSEcCtD
Ezogabine—Liver function test abnormal—Dactinomycin—uterine cancer	0.00193	0.00569	CcSEcCtD
Ezogabine—Eye disorder—Progesterone—uterine cancer	0.00191	0.00564	CcSEcCtD
Ezogabine—UGT1A1—renal system—uterine cancer	0.00188	0.0619	CbGeAlD
Ezogabine—Urinary tract disorder—Medroxyprogesterone Acetate—uterine cancer	0.00183	0.0054	CcSEcCtD
Ezogabine—Oedema peripheral—Medroxyprogesterone Acetate—uterine cancer	0.00182	0.00539	CcSEcCtD
Ezogabine—Urethral disorder—Medroxyprogesterone Acetate—uterine cancer	0.00181	0.00536	CcSEcCtD
Ezogabine—Alopecia—Progesterone—uterine cancer	0.0018	0.00533	CcSEcCtD
Ezogabine—Dysphagia—Dactinomycin—uterine cancer	0.0018	0.00533	CcSEcCtD
Ezogabine—Mental disorder—Progesterone—uterine cancer	0.00179	0.00529	CcSEcCtD
Ezogabine—Visual impairment—Medroxyprogesterone Acetate—uterine cancer	0.00178	0.00527	CcSEcCtD
Ezogabine—Malnutrition—Progesterone—uterine cancer	0.00178	0.00525	CcSEcCtD
Ezogabine—Eye disorder—Medroxyprogesterone Acetate—uterine cancer	0.00173	0.00511	CcSEcCtD
Ezogabine—Hypokinesia—Epirubicin—uterine cancer	0.00173	0.0051	CcSEcCtD
Ezogabine—Muscle spasms—Progesterone—uterine cancer	0.00171	0.00505	CcSEcCtD
Ezogabine—Neutropenia—Dactinomycin—uterine cancer	0.00169	0.00498	CcSEcCtD
Ezogabine—Vision blurred—Progesterone—uterine cancer	0.00168	0.00495	CcSEcCtD
Ezogabine—Tremor—Progesterone—uterine cancer	0.00167	0.00492	CcSEcCtD
Ezogabine—Ill-defined disorder—Progesterone—uterine cancer	0.00165	0.00487	CcSEcCtD
Ezogabine—Alopecia—Medroxyprogesterone Acetate—uterine cancer	0.00164	0.00483	CcSEcCtD
Ezogabine—Nystagmus—Epirubicin—uterine cancer	0.00163	0.00482	CcSEcCtD
Ezogabine—Mental disorder—Medroxyprogesterone Acetate—uterine cancer	0.00162	0.00479	CcSEcCtD
Ezogabine—NAT2—Metapathway biotransformation—AKR1C1—uterine cancer	0.00162	0.013	CbGpPWpGaD
Ezogabine—Malnutrition—Medroxyprogesterone Acetate—uterine cancer	0.00161	0.00476	CcSEcCtD
Ezogabine—Malaise—Progesterone—uterine cancer	0.0016	0.00474	CcSEcCtD
Ezogabine—Hypokinesia—Doxorubicin—uterine cancer	0.0016	0.00472	CcSEcCtD
Ezogabine—Vertigo—Progesterone—uterine cancer	0.0016	0.00472	CcSEcCtD
Ezogabine—Syncope—Progesterone—uterine cancer	0.00159	0.00471	CcSEcCtD
Ezogabine—Loss of consciousness—Progesterone—uterine cancer	0.00156	0.00462	CcSEcCtD
Ezogabine—Muscle spasms—Medroxyprogesterone Acetate—uterine cancer	0.00155	0.00458	CcSEcCtD
Ezogabine—Nystagmus—Doxorubicin—uterine cancer	0.00151	0.00446	CcSEcCtD
Ezogabine—Tremor—Medroxyprogesterone Acetate—uterine cancer	0.00151	0.00446	CcSEcCtD
Ezogabine—Anxiety—Progesterone—uterine cancer	0.00151	0.00446	CcSEcCtD
Ezogabine—UGT1A1—Aryl Hydrocarbon Receptor Pathway—NFE2L2—uterine cancer	0.00151	0.0121	CbGpPWpGaD
Ezogabine—UGT1A9—Aryl Hydrocarbon Receptor Pathway—NFE2L2—uterine cancer	0.00151	0.0121	CbGpPWpGaD
Ezogabine—Discomfort—Progesterone—uterine cancer	0.0015	0.00442	CcSEcCtD
Ezogabine—Ill-defined disorder—Medroxyprogesterone Acetate—uterine cancer	0.00149	0.00442	CcSEcCtD
Ezogabine—Dry mouth—Progesterone—uterine cancer	0.00148	0.00437	CcSEcCtD
Ezogabine—CYP2A6—Fluoropyrimidine Activity—RRM2—uterine cancer	0.00147	0.0118	CbGpPWpGaD
Ezogabine—Confusional state—Progesterone—uterine cancer	0.00146	0.00432	CcSEcCtD
Ezogabine—Malaise—Medroxyprogesterone Acetate—uterine cancer	0.00145	0.00429	CcSEcCtD
Ezogabine—Vertigo—Medroxyprogesterone Acetate—uterine cancer	0.00145	0.00428	CcSEcCtD
Ezogabine—Syncope—Medroxyprogesterone Acetate—uterine cancer	0.00144	0.00427	CcSEcCtD
Ezogabine—Infection—Progesterone—uterine cancer	0.00144	0.00426	CcSEcCtD
Ezogabine—UGT1A4—Metapathway biotransformation—AKR1B10—uterine cancer	0.00144	0.0115	CbGpPWpGaD
Ezogabine—Shock—Progesterone—uterine cancer	0.00143	0.00422	CcSEcCtD
Ezogabine—KCNQ3—Neuronal System—ABCC9—uterine cancer	0.00143	0.0115	CbGpPWpGaD
Ezogabine—KCNQ2—Neuronal System—ABCC9—uterine cancer	0.00143	0.0115	CbGpPWpGaD
Ezogabine—Nervous system disorder—Progesterone—uterine cancer	0.00142	0.0042	CcSEcCtD
Ezogabine—NAT2—Metapathway biotransformation—GPX3—uterine cancer	0.00142	0.0114	CbGpPWpGaD
Ezogabine—Loss of consciousness—Medroxyprogesterone Acetate—uterine cancer	0.00142	0.00418	CcSEcCtD
Ezogabine—Hyperhidrosis—Progesterone—uterine cancer	0.0014	0.00414	CcSEcCtD
Ezogabine—KCNQ3—Developmental Biology—PLXNA3—uterine cancer	0.0014	0.0113	CbGpPWpGaD
Ezogabine—KCNQ2—Developmental Biology—PLXNA3—uterine cancer	0.0014	0.0113	CbGpPWpGaD
Ezogabine—Anxiety—Medroxyprogesterone Acetate—uterine cancer	0.00137	0.00404	CcSEcCtD
Ezogabine—Discomfort—Medroxyprogesterone Acetate—uterine cancer	0.00136	0.004	CcSEcCtD
Ezogabine—Dry mouth—Medroxyprogesterone Acetate—uterine cancer	0.00134	0.00396	CcSEcCtD
Ezogabine—NAT2—Biological oxidations—CYP11A1—uterine cancer	0.00134	0.0107	CbGpPWpGaD
Ezogabine—UGT1A4—Metapathway biotransformation—AKR1B1—uterine cancer	0.00133	0.0107	CbGpPWpGaD
Ezogabine—Confusional state—Medroxyprogesterone Acetate—uterine cancer	0.00133	0.00392	CcSEcCtD
Ezogabine—NAT2—Metapathway biotransformation—CYP11A1—uterine cancer	0.00132	0.0106	CbGpPWpGaD
Ezogabine—Infection—Medroxyprogesterone Acetate—uterine cancer	0.00131	0.00386	CcSEcCtD
Ezogabine—Dysphagia—Etoposide—uterine cancer	0.00131	0.00386	CcSEcCtD
Ezogabine—Paraesthesia—Progesterone—uterine cancer	0.0013	0.00385	CcSEcCtD
Ezogabine—Dyspnoea—Progesterone—uterine cancer	0.00129	0.00382	CcSEcCtD
Ezogabine—Shock—Medroxyprogesterone Acetate—uterine cancer	0.00129	0.00382	CcSEcCtD
Ezogabine—Skin discolouration—Epirubicin—uterine cancer	0.00129	0.00381	CcSEcCtD
Ezogabine—Somnolence—Progesterone—uterine cancer	0.00129	0.00381	CcSEcCtD
Ezogabine—Nervous system disorder—Medroxyprogesterone Acetate—uterine cancer	0.00129	0.00381	CcSEcCtD
Ezogabine—Thrombocytopenia—Medroxyprogesterone Acetate—uterine cancer	0.00129	0.0038	CcSEcCtD
Ezogabine—Dyspepsia—Progesterone—uterine cancer	0.00128	0.00377	CcSEcCtD
Ezogabine—Alopecia—Dactinomycin—uterine cancer	0.00128	0.00377	CcSEcCtD
Ezogabine—Hyperhidrosis—Medroxyprogesterone Acetate—uterine cancer	0.00127	0.00375	CcSEcCtD
Ezogabine—Gastrointestinal disorder—Progesterone—uterine cancer	0.00125	0.0037	CcSEcCtD
Ezogabine—Fatigue—Progesterone—uterine cancer	0.00125	0.0037	CcSEcCtD
Ezogabine—NAT2—Metapathway biotransformation—AKR1C3—uterine cancer	0.00124	0.01	CbGpPWpGaD
Ezogabine—Constipation—Progesterone—uterine cancer	0.00124	0.00367	CcSEcCtD
Ezogabine—Dysarthria—Epirubicin—uterine cancer	0.00123	0.00364	CcSEcCtD
Ezogabine—Neutropenia—Etoposide—uterine cancer	0.00122	0.00361	CcSEcCtD
Ezogabine—Feeling abnormal—Progesterone—uterine cancer	0.0012	0.00353	CcSEcCtD
Ezogabine—Gait disturbance—Epirubicin—uterine cancer	0.00119	0.00353	CcSEcCtD
Ezogabine—Skin discolouration—Doxorubicin—uterine cancer	0.00119	0.00353	CcSEcCtD
Ezogabine—UGT1A3—Metapathway biotransformation—AKR1B10—uterine cancer	0.00119	0.00959	CbGpPWpGaD
Ezogabine—Coordination abnormal—Epirubicin—uterine cancer	0.00119	0.00351	CcSEcCtD
Ezogabine—Paraesthesia—Medroxyprogesterone Acetate—uterine cancer	0.00118	0.00349	CcSEcCtD
Ezogabine—Dyspnoea—Medroxyprogesterone Acetate—uterine cancer	0.00117	0.00346	CcSEcCtD
Ezogabine—Somnolence—Medroxyprogesterone Acetate—uterine cancer	0.00117	0.00345	CcSEcCtD
Ezogabine—Ill-defined disorder—Dactinomycin—uterine cancer	0.00117	0.00344	CcSEcCtD
Ezogabine—Infestation NOS—Etoposide—uterine cancer	0.00116	0.00344	CcSEcCtD
Ezogabine—Infestation—Etoposide—uterine cancer	0.00116	0.00344	CcSEcCtD
Ezogabine—Dyspepsia—Medroxyprogesterone Acetate—uterine cancer	0.00116	0.00342	CcSEcCtD
Ezogabine—CYP2A6—vagina—uterine cancer	0.00115	0.0378	CbGeAlD
Ezogabine—Dysarthria—Doxorubicin—uterine cancer	0.00114	0.00337	CcSEcCtD
Ezogabine—Gastrointestinal disorder—Medroxyprogesterone Acetate—uterine cancer	0.00114	0.00335	CcSEcCtD
Ezogabine—Fatigue—Medroxyprogesterone Acetate—uterine cancer	0.00113	0.00335	CcSEcCtD
Ezogabine—Malaise—Dactinomycin—uterine cancer	0.00113	0.00335	CcSEcCtD
Ezogabine—Leukopenia—Dactinomycin—uterine cancer	0.00112	0.00332	CcSEcCtD
Ezogabine—Constipation—Medroxyprogesterone Acetate—uterine cancer	0.00112	0.00332	CcSEcCtD
Ezogabine—UGT1A3—Metapathway biotransformation—AKR1B1—uterine cancer	0.00111	0.00892	CbGpPWpGaD
Ezogabine—Gait disturbance—Doxorubicin—uterine cancer	0.00111	0.00327	CcSEcCtD
Ezogabine—Hepatobiliary disease—Etoposide—uterine cancer	0.0011	0.00325	CcSEcCtD
Ezogabine—Coordination abnormal—Doxorubicin—uterine cancer	0.0011	0.00325	CcSEcCtD
Ezogabine—Feeling abnormal—Medroxyprogesterone Acetate—uterine cancer	0.00108	0.0032	CcSEcCtD
Ezogabine—Coma—Epirubicin—uterine cancer	0.00107	0.00315	CcSEcCtD
Ezogabine—Discomfort—Dactinomycin—uterine cancer	0.00106	0.00312	CcSEcCtD
Ezogabine—UGT1A4—NRF2 pathway—NFE2L2—uterine cancer	0.00104	0.00838	CbGpPWpGaD
Ezogabine—Asthenia—Progesterone—uterine cancer	0.00104	0.00308	CcSEcCtD
Ezogabine—Urinary tract disorder—Etoposide—uterine cancer	0.00103	0.00305	CcSEcCtD
Ezogabine—Urethral disorder—Etoposide—uterine cancer	0.00102	0.00303	CcSEcCtD
Ezogabine—Infection—Dactinomycin—uterine cancer	0.00102	0.00301	CcSEcCtD
Ezogabine—Thrombocytopenia—Dactinomycin—uterine cancer	0.001	0.00297	CcSEcCtD
Ezogabine—UGT1A4—NRF2 pathway—GPX3—uterine cancer	0.000994	0.00799	CbGpPWpGaD
Ezogabine—Coma—Doxorubicin—uterine cancer	0.000986	0.00291	CcSEcCtD
Ezogabine—NAT2—Biological oxidations—CYP19A1—uterine cancer	0.000983	0.0079	CbGpPWpGaD
Ezogabine—UGT1A4—Metapathway biotransformation—AKR1C1—uterine cancer	0.00098	0.00787	CbGpPWpGaD
Ezogabine—Eye disorder—Etoposide—uterine cancer	0.000976	0.00288	CcSEcCtD
Ezogabine—NAT2—Metapathway biotransformation—CYP19A1—uterine cancer	0.00097	0.0078	CbGpPWpGaD
Ezogabine—Dizziness—Progesterone—uterine cancer	0.000959	0.00283	CcSEcCtD
Ezogabine—Asthenia—Medroxyprogesterone Acetate—uterine cancer	0.000943	0.00279	CcSEcCtD
Ezogabine—Alopecia—Etoposide—uterine cancer	0.000923	0.00273	CcSEcCtD
Ezogabine—Rash—Progesterone—uterine cancer	0.000915	0.0027	CcSEcCtD
Ezogabine—Dermatitis—Progesterone—uterine cancer	0.000914	0.0027	CcSEcCtD
Ezogabine—Increased appetite—Epirubicin—uterine cancer	0.000901	0.00266	CcSEcCtD
Ezogabine—Fatigue—Dactinomycin—uterine cancer	0.000884	0.00261	CcSEcCtD
Ezogabine—Muscle spasms—Etoposide—uterine cancer	0.000874	0.00258	CcSEcCtD
Ezogabine—Dizziness—Medroxyprogesterone Acetate—uterine cancer	0.000869	0.00257	CcSEcCtD
Ezogabine—UGT1A3—NRF2 pathway—NFE2L2—uterine cancer	0.000866	0.00696	CbGpPWpGaD
Ezogabine—Nausea—Progesterone—uterine cancer	0.000862	0.00255	CcSEcCtD
Ezogabine—UGT1A4—Metapathway biotransformation—GPX3—uterine cancer	0.00086	0.00691	CbGpPWpGaD
Ezogabine—Diplopia—Epirubicin—uterine cancer	0.000847	0.0025	CcSEcCtD
Ezogabine—Osteoarthritis—Epirubicin—uterine cancer	0.000847	0.0025	CcSEcCtD
Ezogabine—Feeling abnormal—Dactinomycin—uterine cancer	0.000845	0.0025	CcSEcCtD
Ezogabine—Ill-defined disorder—Etoposide—uterine cancer	0.000844	0.00249	CcSEcCtD
Ezogabine—Increased appetite—Doxorubicin—uterine cancer	0.000834	0.00246	CcSEcCtD
Ezogabine—CYP2A6—Cytochrome P450 - arranged by substrate type—CYP11A1—uterine cancer	0.000833	0.00669	CbGpPWpGaD
Ezogabine—Rash—Medroxyprogesterone Acetate—uterine cancer	0.000829	0.00245	CcSEcCtD
Ezogabine—Dermatitis—Medroxyprogesterone Acetate—uterine cancer	0.000828	0.00245	CcSEcCtD
Ezogabine—UGT1A3—NRF2 pathway—GPX3—uterine cancer	0.000826	0.00664	CbGpPWpGaD
Ezogabine—UGT1A1—Metapathway biotransformation—AKR1B10—uterine cancer	0.000825	0.00663	CbGpPWpGaD
Ezogabine—UGT1A9—Metapathway biotransformation—AKR1B10—uterine cancer	0.000825	0.00663	CbGpPWpGaD
Ezogabine—CYP2A6—Oxidation by Cytochrome P450—CYP11A1—uterine cancer	0.000822	0.0066	CbGpPWpGaD
Ezogabine—Malaise—Etoposide—uterine cancer	0.00082	0.00242	CcSEcCtD
Ezogabine—Vertigo—Etoposide—uterine cancer	0.000817	0.00241	CcSEcCtD
Ezogabine—UGT1A3—Metapathway biotransformation—AKR1C1—uterine cancer	0.000814	0.00655	CbGpPWpGaD
Ezogabine—Leukopenia—Etoposide—uterine cancer	0.000814	0.0024	CcSEcCtD
Ezogabine—UGT1A4—Biological oxidations—CYP11A1—uterine cancer	0.00081	0.00651	CbGpPWpGaD
Ezogabine—Loss of consciousness—Etoposide—uterine cancer	0.000799	0.00236	CcSEcCtD
Ezogabine—UGT1A4—Metapathway biotransformation—CYP11A1—uterine cancer	0.000799	0.00642	CbGpPWpGaD
Ezogabine—Osteoarthritis—Doxorubicin—uterine cancer	0.000783	0.00231	CcSEcCtD
Ezogabine—Diplopia—Doxorubicin—uterine cancer	0.000783	0.00231	CcSEcCtD
Ezogabine—Liver function test abnormal—Epirubicin—uterine cancer	0.000782	0.00231	CcSEcCtD
Ezogabine—Nausea—Medroxyprogesterone Acetate—uterine cancer	0.000781	0.00231	CcSEcCtD
Ezogabine—UGT1A4—Aryl Hydrocarbon Receptor Pathway—CDKN1B—uterine cancer	0.000777	0.00624	CbGpPWpGaD
Ezogabine—UGT1A1—Metapathway biotransformation—AKR1B1—uterine cancer	0.000767	0.00616	CbGpPWpGaD
Ezogabine—UGT1A9—Metapathway biotransformation—AKR1B1—uterine cancer	0.000767	0.00616	CbGpPWpGaD
Ezogabine—Discomfort—Etoposide—uterine cancer	0.000765	0.00226	CcSEcCtD
Ezogabine—UGT1A4—Metapathway biotransformation—AKR1C3—uterine cancer	0.000754	0.00606	CbGpPWpGaD
Ezogabine—Confusional state—Etoposide—uterine cancer	0.000748	0.00221	CcSEcCtD
Ezogabine—CYP2A6—Fluoropyrimidine Activity—MTHFR—uterine cancer	0.000743	0.00597	CbGpPWpGaD
Ezogabine—Infection—Etoposide—uterine cancer	0.000737	0.00218	CcSEcCtD
Ezogabine—KCNQ2—Developmental Biology—HNF1B—uterine cancer	0.000736	0.00592	CbGpPWpGaD
Ezogabine—KCNQ3—Developmental Biology—HNF1B—uterine cancer	0.000736	0.00592	CbGpPWpGaD
Ezogabine—Asthenia—Dactinomycin—uterine cancer	0.000736	0.00217	CcSEcCtD
Ezogabine—Influenza—Epirubicin—uterine cancer	0.000732	0.00216	CcSEcCtD
Ezogabine—Dysphagia—Epirubicin—uterine cancer	0.000732	0.00216	CcSEcCtD
Ezogabine—Thrombocytopenia—Etoposide—uterine cancer	0.000727	0.00215	CcSEcCtD
Ezogabine—Liver function test abnormal—Doxorubicin—uterine cancer	0.000723	0.00214	CcSEcCtD
Ezogabine—Hyperhidrosis—Etoposide—uterine cancer	0.000718	0.00212	CcSEcCtD
Ezogabine—UGT1A3—Metapathway biotransformation—GPX3—uterine cancer	0.000715	0.00575	CbGpPWpGaD
Ezogabine—Dysuria—Epirubicin—uterine cancer	0.000684	0.00202	CcSEcCtD
Ezogabine—Neutropenia—Epirubicin—uterine cancer	0.000684	0.00202	CcSEcCtD
Ezogabine—UGT1A4—Aryl Hydrocarbon Receptor Pathway—EP300—uterine cancer	0.000682	0.00548	CbGpPWpGaD
Ezogabine—Dysphagia—Doxorubicin—uterine cancer	0.000677	0.002	CcSEcCtD
Ezogabine—Influenza—Doxorubicin—uterine cancer	0.000677	0.002	CcSEcCtD
Ezogabine—CYP2A6—Phase 1 - Functionalization of compounds—CYP11A1—uterine cancer	0.000675	0.00542	CbGpPWpGaD
Ezogabine—UGT1A3—Biological oxidations—CYP11A1—uterine cancer	0.000673	0.00541	CbGpPWpGaD
Ezogabine—Paraesthesia—Etoposide—uterine cancer	0.000666	0.00197	CcSEcCtD
Ezogabine—Weight increased—Epirubicin—uterine cancer	0.000666	0.00197	CcSEcCtD
Ezogabine—CYP2A6—Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis—VEGFA—uterine cancer	0.000666	0.00535	CbGpPWpGaD
Ezogabine—UGT1A3—Metapathway biotransformation—CYP11A1—uterine cancer	0.000664	0.00534	CbGpPWpGaD
Ezogabine—Dyspnoea—Etoposide—uterine cancer	0.000662	0.00195	CcSEcCtD
Ezogabine—Somnolence—Etoposide—uterine cancer	0.00066	0.00195	CcSEcCtD
Ezogabine—Infestation NOS—Epirubicin—uterine cancer	0.000652	0.00193	CcSEcCtD
Ezogabine—Infestation—Epirubicin—uterine cancer	0.000652	0.00193	CcSEcCtD
Ezogabine—Rash—Dactinomycin—uterine cancer	0.000647	0.00191	CcSEcCtD
Ezogabine—UGT1A3—Aryl Hydrocarbon Receptor Pathway—CDKN1B—uterine cancer	0.000646	0.00519	CbGpPWpGaD
Ezogabine—Gastrointestinal disorder—Etoposide—uterine cancer	0.000641	0.00189	CcSEcCtD
Ezogabine—Fatigue—Etoposide—uterine cancer	0.00064	0.00189	CcSEcCtD
Ezogabine—Constipation—Etoposide—uterine cancer	0.000635	0.00188	CcSEcCtD
Ezogabine—Dysuria—Doxorubicin—uterine cancer	0.000633	0.00187	CcSEcCtD
Ezogabine—Neutropenia—Doxorubicin—uterine cancer	0.000633	0.00187	CcSEcCtD
Ezogabine—UGT1A3—Metapathway biotransformation—AKR1C3—uterine cancer	0.000627	0.00504	CbGpPWpGaD
Ezogabine—Haematuria—Epirubicin—uterine cancer	0.000622	0.00184	CcSEcCtD
Ezogabine—Hepatobiliary disease—Epirubicin—uterine cancer	0.000617	0.00182	CcSEcCtD
Ezogabine—Weight increased—Doxorubicin—uterine cancer	0.000616	0.00182	CcSEcCtD
Ezogabine—CYP2A6—Cytochrome P450 - arranged by substrate type—CYP19A1—uterine cancer	0.000612	0.00492	CbGpPWpGaD
Ezogabine—Feeling abnormal—Etoposide—uterine cancer	0.000612	0.00181	CcSEcCtD
Ezogabine—Nausea—Dactinomycin—uterine cancer	0.000609	0.0018	CcSEcCtD
Ezogabine—CYP2A6—Oxidation by Cytochrome P450—CYP19A1—uterine cancer	0.000604	0.00486	CbGpPWpGaD
Ezogabine—Infestation—Doxorubicin—uterine cancer	0.000604	0.00178	CcSEcCtD
Ezogabine—Infestation NOS—Doxorubicin—uterine cancer	0.000604	0.00178	CcSEcCtD
Ezogabine—UGT1A1—NRF2 pathway—NFE2L2—uterine cancer	0.000599	0.00481	CbGpPWpGaD
Ezogabine—UGT1A9—NRF2 pathway—NFE2L2—uterine cancer	0.000599	0.00481	CbGpPWpGaD
Ezogabine—UGT1A4—Biological oxidations—CYP19A1—uterine cancer	0.000596	0.00479	CbGpPWpGaD
Ezogabine—UGT1A4—Metapathway biotransformation—CYP19A1—uterine cancer	0.000588	0.00472	CbGpPWpGaD
Ezogabine—Urinary tract disorder—Epirubicin—uterine cancer	0.000578	0.00171	CcSEcCtD
Ezogabine—Oedema peripheral—Epirubicin—uterine cancer	0.000577	0.0017	CcSEcCtD
Ezogabine—Haematuria—Doxorubicin—uterine cancer	0.000576	0.0017	CcSEcCtD
Ezogabine—Urethral disorder—Epirubicin—uterine cancer	0.000574	0.0017	CcSEcCtD
Ezogabine—UGT1A1—NRF2 pathway—GPX3—uterine cancer	0.000571	0.00459	CbGpPWpGaD
Ezogabine—UGT1A9—NRF2 pathway—GPX3—uterine cancer	0.000571	0.00459	CbGpPWpGaD
Ezogabine—Hepatobiliary disease—Doxorubicin—uterine cancer	0.000571	0.00169	CcSEcCtD
Ezogabine—UGT1A3—Aryl Hydrocarbon Receptor Pathway—EP300—uterine cancer	0.000567	0.00456	CbGpPWpGaD
Ezogabine—Visual impairment—Epirubicin—uterine cancer	0.000564	0.00167	CcSEcCtD
Ezogabine—UGT1A1—Metapathway biotransformation—AKR1C1—uterine cancer	0.000563	0.00452	CbGpPWpGaD
Ezogabine—UGT1A9—Metapathway biotransformation—AKR1C1—uterine cancer	0.000563	0.00452	CbGpPWpGaD
Ezogabine—Eye disorder—Epirubicin—uterine cancer	0.000547	0.00162	CcSEcCtD
Ezogabine—Urinary tract disorder—Doxorubicin—uterine cancer	0.000535	0.00158	CcSEcCtD
Ezogabine—Oedema peripheral—Doxorubicin—uterine cancer	0.000534	0.00158	CcSEcCtD
Ezogabine—Asthenia—Etoposide—uterine cancer	0.000533	0.00157	CcSEcCtD
Ezogabine—Urethral disorder—Doxorubicin—uterine cancer	0.000531	0.00157	CcSEcCtD
Ezogabine—NAT2—Metabolism—NDUFB11—uterine cancer	0.000528	0.00425	CbGpPWpGaD
Ezogabine—NAT2—Metabolism—SRD5A2—uterine cancer	0.000528	0.00425	CbGpPWpGaD
Ezogabine—Visual impairment—Doxorubicin—uterine cancer	0.000522	0.00154	CcSEcCtD
Ezogabine—Alopecia—Epirubicin—uterine cancer	0.000517	0.00153	CcSEcCtD
Ezogabine—Mental disorder—Epirubicin—uterine cancer	0.000513	0.00152	CcSEcCtD
Ezogabine—Malnutrition—Epirubicin—uterine cancer	0.00051	0.00151	CcSEcCtD
Ezogabine—Eye disorder—Doxorubicin—uterine cancer	0.000506	0.0015	CcSEcCtD
Ezogabine—CYP2A6—Phase 1 - Functionalization of compounds—CYP19A1—uterine cancer	0.000497	0.00399	CbGpPWpGaD
Ezogabine—UGT1A3—Biological oxidations—CYP19A1—uterine cancer	0.000495	0.00398	CbGpPWpGaD
Ezogabine—UGT1A1—Metapathway biotransformation—GPX3—uterine cancer	0.000494	0.00397	CbGpPWpGaD
Ezogabine—UGT1A9—Metapathway biotransformation—GPX3—uterine cancer	0.000494	0.00397	CbGpPWpGaD
Ezogabine—Dizziness—Etoposide—uterine cancer	0.000491	0.00145	CcSEcCtD
Ezogabine—Muscle spasms—Epirubicin—uterine cancer	0.00049	0.00145	CcSEcCtD
Ezogabine—UGT1A3—Metapathway biotransformation—CYP19A1—uterine cancer	0.000488	0.00393	CbGpPWpGaD
Ezogabine—Vision blurred—Epirubicin—uterine cancer	0.00048	0.00142	CcSEcCtD
Ezogabine—Alopecia—Doxorubicin—uterine cancer	0.000479	0.00141	CcSEcCtD
Ezogabine—Mental disorder—Doxorubicin—uterine cancer	0.000475	0.0014	CcSEcCtD
Ezogabine—Ill-defined disorder—Epirubicin—uterine cancer	0.000473	0.0014	CcSEcCtD
Ezogabine—Malnutrition—Doxorubicin—uterine cancer	0.000472	0.00139	CcSEcCtD
Ezogabine—Rash—Etoposide—uterine cancer	0.000468	0.00138	CcSEcCtD
Ezogabine—Dermatitis—Etoposide—uterine cancer	0.000468	0.00138	CcSEcCtD
Ezogabine—UGT1A1—Biological oxidations—CYP11A1—uterine cancer	0.000465	0.00374	CbGpPWpGaD
Ezogabine—UGT1A9—Biological oxidations—CYP11A1—uterine cancer	0.000465	0.00374	CbGpPWpGaD
Ezogabine—CYP2A6—NRF2 pathway—NFE2L2—uterine cancer	0.000461	0.00371	CbGpPWpGaD
Ezogabine—Malaise—Epirubicin—uterine cancer	0.00046	0.00136	CcSEcCtD
Ezogabine—UGT1A1—Metapathway biotransformation—CYP11A1—uterine cancer	0.000459	0.00369	CbGpPWpGaD
Ezogabine—UGT1A9—Metapathway biotransformation—CYP11A1—uterine cancer	0.000459	0.00369	CbGpPWpGaD
Ezogabine—Vertigo—Epirubicin—uterine cancer	0.000458	0.00135	CcSEcCtD
Ezogabine—Syncope—Epirubicin—uterine cancer	0.000457	0.00135	CcSEcCtD
Ezogabine—Leukopenia—Epirubicin—uterine cancer	0.000456	0.00135	CcSEcCtD
Ezogabine—Muscle spasms—Doxorubicin—uterine cancer	0.000454	0.00134	CcSEcCtD
Ezogabine—Loss of consciousness—Epirubicin—uterine cancer	0.000448	0.00132	CcSEcCtD
Ezogabine—UGT1A1—Aryl Hydrocarbon Receptor Pathway—CDKN1B—uterine cancer	0.000446	0.00359	CbGpPWpGaD
Ezogabine—UGT1A9—Aryl Hydrocarbon Receptor Pathway—CDKN1B—uterine cancer	0.000446	0.00359	CbGpPWpGaD
Ezogabine—Vision blurred—Doxorubicin—uterine cancer	0.000445	0.00131	CcSEcCtD
Ezogabine—Nausea—Etoposide—uterine cancer	0.000441	0.0013	CcSEcCtD
Ezogabine—CYP2A6—NRF2 pathway—GPX3—uterine cancer	0.00044	0.00354	CbGpPWpGaD
Ezogabine—Ill-defined disorder—Doxorubicin—uterine cancer	0.000438	0.00129	CcSEcCtD
Ezogabine—UGT1A1—Metapathway biotransformation—AKR1C3—uterine cancer	0.000433	0.00348	CbGpPWpGaD
Ezogabine—UGT1A9—Metapathway biotransformation—AKR1C3—uterine cancer	0.000433	0.00348	CbGpPWpGaD
Ezogabine—Anxiety—Epirubicin—uterine cancer	0.000433	0.00128	CcSEcCtD
Ezogabine—Discomfort—Epirubicin—uterine cancer	0.000429	0.00127	CcSEcCtD
Ezogabine—Malaise—Doxorubicin—uterine cancer	0.000425	0.00126	CcSEcCtD
Ezogabine—Dry mouth—Epirubicin—uterine cancer	0.000424	0.00125	CcSEcCtD
Ezogabine—Vertigo—Doxorubicin—uterine cancer	0.000424	0.00125	CcSEcCtD
Ezogabine—Syncope—Doxorubicin—uterine cancer	0.000423	0.00125	CcSEcCtD
Ezogabine—Leukopenia—Doxorubicin—uterine cancer	0.000422	0.00125	CcSEcCtD
Ezogabine—Confusional state—Epirubicin—uterine cancer	0.00042	0.00124	CcSEcCtD
Ezogabine—Loss of consciousness—Doxorubicin—uterine cancer	0.000415	0.00122	CcSEcCtD
Ezogabine—Infection—Epirubicin—uterine cancer	0.000413	0.00122	CcSEcCtD
Ezogabine—UGT1A9—Metabolism of lipids and lipoproteins—SRD5A2—uterine cancer	0.000413	0.00332	CbGpPWpGaD
Ezogabine—Shock—Epirubicin—uterine cancer	0.000409	0.00121	CcSEcCtD
Ezogabine—Nervous system disorder—Epirubicin—uterine cancer	0.000408	0.00121	CcSEcCtD
Ezogabine—Thrombocytopenia—Epirubicin—uterine cancer	0.000407	0.0012	CcSEcCtD
Ezogabine—Hyperhidrosis—Epirubicin—uterine cancer	0.000402	0.00119	CcSEcCtD
Ezogabine—Anxiety—Doxorubicin—uterine cancer	0.0004	0.00118	CcSEcCtD
Ezogabine—Discomfort—Doxorubicin—uterine cancer	0.000397	0.00117	CcSEcCtD
Ezogabine—Dry mouth—Doxorubicin—uterine cancer	0.000393	0.00116	CcSEcCtD
Ezogabine—UGT1A1—Aryl Hydrocarbon Receptor Pathway—EP300—uterine cancer	0.000392	0.00315	CbGpPWpGaD
Ezogabine—UGT1A9—Aryl Hydrocarbon Receptor Pathway—EP300—uterine cancer	0.000392	0.00315	CbGpPWpGaD
Ezogabine—Confusional state—Doxorubicin—uterine cancer	0.000388	0.00115	CcSEcCtD
Ezogabine—Infection—Doxorubicin—uterine cancer	0.000382	0.00113	CcSEcCtD
Ezogabine—NAT2—Metabolism—STAR—uterine cancer	0.000382	0.00307	CbGpPWpGaD
Ezogabine—NAT2—Metabolism—AKR1B1—uterine cancer	0.000382	0.00307	CbGpPWpGaD
Ezogabine—Shock—Doxorubicin—uterine cancer	0.000379	0.00112	CcSEcCtD
Ezogabine—Nervous system disorder—Doxorubicin—uterine cancer	0.000378	0.00112	CcSEcCtD
Ezogabine—Thrombocytopenia—Doxorubicin—uterine cancer	0.000377	0.00111	CcSEcCtD
Ezogabine—KCNQ2—Axon guidance—MET—uterine cancer	0.000374	0.003	CbGpPWpGaD
Ezogabine—KCNQ3—Axon guidance—MET—uterine cancer	0.000374	0.003	CbGpPWpGaD
Ezogabine—Paraesthesia—Epirubicin—uterine cancer	0.000374	0.0011	CcSEcCtD
Ezogabine—Hyperhidrosis—Doxorubicin—uterine cancer	0.000372	0.0011	CcSEcCtD
Ezogabine—Dyspnoea—Epirubicin—uterine cancer	0.000371	0.0011	CcSEcCtD
Ezogabine—Somnolence—Epirubicin—uterine cancer	0.00037	0.00109	CcSEcCtD
Ezogabine—Dyspepsia—Epirubicin—uterine cancer	0.000366	0.00108	CcSEcCtD
Ezogabine—Gastrointestinal disorder—Epirubicin—uterine cancer	0.000359	0.00106	CcSEcCtD
Ezogabine—Fatigue—Epirubicin—uterine cancer	0.000359	0.00106	CcSEcCtD
Ezogabine—CYP2A6—Biological oxidations—CYP11A1—uterine cancer	0.000358	0.00288	CbGpPWpGaD
Ezogabine—Constipation—Epirubicin—uterine cancer	0.000356	0.00105	CcSEcCtD
Ezogabine—Paraesthesia—Doxorubicin—uterine cancer	0.000346	0.00102	CcSEcCtD
Ezogabine—Dyspnoea—Doxorubicin—uterine cancer	0.000343	0.00101	CcSEcCtD
Ezogabine—Feeling abnormal—Epirubicin—uterine cancer	0.000343	0.00101	CcSEcCtD
Ezogabine—Somnolence—Doxorubicin—uterine cancer	0.000342	0.00101	CcSEcCtD
Ezogabine—UGT1A1—Biological oxidations—CYP19A1—uterine cancer	0.000342	0.00275	CbGpPWpGaD
Ezogabine—UGT1A9—Biological oxidations—CYP19A1—uterine cancer	0.000342	0.00275	CbGpPWpGaD
Ezogabine—Dyspepsia—Doxorubicin—uterine cancer	0.000339	0.001	CcSEcCtD
Ezogabine—UGT1A1—Metapathway biotransformation—CYP19A1—uterine cancer	0.000337	0.00271	CbGpPWpGaD
Ezogabine—UGT1A9—Metapathway biotransformation—CYP19A1—uterine cancer	0.000337	0.00271	CbGpPWpGaD
Ezogabine—Gastrointestinal disorder—Doxorubicin—uterine cancer	0.000332	0.000982	CcSEcCtD
Ezogabine—Fatigue—Doxorubicin—uterine cancer	0.000332	0.000981	CcSEcCtD
Ezogabine—Constipation—Doxorubicin—uterine cancer	0.000329	0.000973	CcSEcCtD
Ezogabine—KCNQ2—Developmental Biology—SMAD3—uterine cancer	0.000325	0.00262	CbGpPWpGaD
Ezogabine—KCNQ3—Developmental Biology—SMAD3—uterine cancer	0.000325	0.00262	CbGpPWpGaD
Ezogabine—UGT1A4—Metabolism—NDUFB11—uterine cancer	0.00032	0.00257	CbGpPWpGaD
Ezogabine—UGT1A4—Metabolism—SRD5A2—uterine cancer	0.00032	0.00257	CbGpPWpGaD
Ezogabine—Feeling abnormal—Doxorubicin—uterine cancer	0.000317	0.000937	CcSEcCtD
Ezogabine—KCNQ5—Neuronal System—HRAS—uterine cancer	0.000317	0.00255	CbGpPWpGaD
Ezogabine—KCNQ4—Neuronal System—HRAS—uterine cancer	0.000317	0.00255	CbGpPWpGaD
Ezogabine—NAT2—Metabolism—POLD1—uterine cancer	0.0003	0.00241	CbGpPWpGaD
Ezogabine—Asthenia—Epirubicin—uterine cancer	0.000299	0.000882	CcSEcCtD
Ezogabine—UGT1A9—Metabolism of lipids and lipoproteins—AKR1B1—uterine cancer	0.000298	0.0024	CbGpPWpGaD
Ezogabine—UGT1A9—Metabolism of lipids and lipoproteins—STAR—uterine cancer	0.000298	0.0024	CbGpPWpGaD
Ezogabine—CYP2A6—Fluoropyrimidine Activity—TP53—uterine cancer	0.000282	0.00227	CbGpPWpGaD
Ezogabine—NAT2—Metabolism—AKR1C1—uterine cancer	0.00028	0.00225	CbGpPWpGaD
Ezogabine—Asthenia—Doxorubicin—uterine cancer	0.000276	0.000816	CcSEcCtD
Ezogabine—Dizziness—Epirubicin—uterine cancer	0.000275	0.000813	CcSEcCtD
Ezogabine—KCNQ2—Axon guidance—ERBB2—uterine cancer	0.000273	0.0022	CbGpPWpGaD
Ezogabine—KCNQ3—Axon guidance—ERBB2—uterine cancer	0.000273	0.0022	CbGpPWpGaD
Ezogabine—KCNQ2—Developmental Biology—MET—uterine cancer	0.000267	0.00214	CbGpPWpGaD
Ezogabine—KCNQ3—Developmental Biology—MET—uterine cancer	0.000267	0.00214	CbGpPWpGaD
Ezogabine—UGT1A3—Metabolism—SRD5A2—uterine cancer	0.000266	0.00214	CbGpPWpGaD
Ezogabine—UGT1A3—Metabolism—NDUFB11—uterine cancer	0.000266	0.00214	CbGpPWpGaD
Ezogabine—CYP2A6—Biological oxidations—CYP19A1—uterine cancer	0.000264	0.00212	CbGpPWpGaD
Ezogabine—Rash—Epirubicin—uterine cancer	0.000262	0.000775	CcSEcCtD
Ezogabine—Dermatitis—Epirubicin—uterine cancer	0.000262	0.000774	CcSEcCtD
Ezogabine—Dizziness—Doxorubicin—uterine cancer	0.000255	0.000752	CcSEcCtD
Ezogabine—NAT2—Metabolism—RRM2—uterine cancer	0.00025	0.00201	CbGpPWpGaD
Ezogabine—Nausea—Epirubicin—uterine cancer	0.000247	0.00073	CcSEcCtD
Ezogabine—Rash—Doxorubicin—uterine cancer	0.000243	0.000717	CcSEcCtD
Ezogabine—NAT2—Metabolism—DCN—uterine cancer	0.000243	0.00195	CbGpPWpGaD
Ezogabine—Dermatitis—Doxorubicin—uterine cancer	0.000243	0.000716	CcSEcCtD
Ezogabine—UGT1A4—Metabolism—AKR1B1—uterine cancer	0.000231	0.00186	CbGpPWpGaD
Ezogabine—UGT1A4—Metabolism—STAR—uterine cancer	0.000231	0.00186	CbGpPWpGaD
Ezogabine—Nausea—Doxorubicin—uterine cancer	0.000229	0.000676	CcSEcCtD
Ezogabine—NAT2—Metabolism—CYP11A1—uterine cancer	0.000229	0.00184	CbGpPWpGaD
Ezogabine—UGT1A9—Metabolism of lipids and lipoproteins—AKR1C1—uterine cancer	0.000219	0.00176	CbGpPWpGaD
Ezogabine—NAT2—Metabolism—AKR1C3—uterine cancer	0.000216	0.00173	CbGpPWpGaD
Ezogabine—KCNQ2—Axon guidance—VEGFA—uterine cancer	0.00021	0.00169	CbGpPWpGaD
Ezogabine—KCNQ3—Axon guidance—VEGFA—uterine cancer	0.00021	0.00169	CbGpPWpGaD
Ezogabine—KCNQ2—Axon guidance—NRAS—uterine cancer	0.000208	0.00167	CbGpPWpGaD
Ezogabine—KCNQ3—Axon guidance—NRAS—uterine cancer	0.000208	0.00167	CbGpPWpGaD
Ezogabine—UGT1A9—PPARA activates gene expression—EP300—uterine cancer	0.000195	0.00157	CbGpPWpGaD
Ezogabine—KCNQ2—Developmental Biology—ERBB2—uterine cancer	0.000195	0.00157	CbGpPWpGaD
Ezogabine—KCNQ3—Developmental Biology—ERBB2—uterine cancer	0.000195	0.00157	CbGpPWpGaD
Ezogabine—UGT1A3—Metabolism—AKR1B1—uterine cancer	0.000192	0.00155	CbGpPWpGaD
Ezogabine—UGT1A3—Metabolism—STAR—uterine cancer	0.000192	0.00155	CbGpPWpGaD
Ezogabine—UGT1A9—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—EP300—uterine cancer	0.000191	0.00153	CbGpPWpGaD
Ezogabine—UGT1A9—Metabolism—SRD5A2—uterine cancer	0.000184	0.00148	CbGpPWpGaD
Ezogabine—UGT1A9—Metabolism—NDUFB11—uterine cancer	0.000184	0.00148	CbGpPWpGaD
Ezogabine—UGT1A1—Metabolism—SRD5A2—uterine cancer	0.000184	0.00148	CbGpPWpGaD
Ezogabine—UGT1A1—Metabolism—NDUFB11—uterine cancer	0.000184	0.00148	CbGpPWpGaD
Ezogabine—UGT1A4—Metabolism—POLD1—uterine cancer	0.000182	0.00146	CbGpPWpGaD
Ezogabine—KCNQ3—Axon guidance—KRAS—uterine cancer	0.000179	0.00144	CbGpPWpGaD
Ezogabine—KCNQ2—Axon guidance—KRAS—uterine cancer	0.000179	0.00144	CbGpPWpGaD
Ezogabine—UGT1A9—Metabolism of lipids and lipoproteins—CYP11A1—uterine cancer	0.000179	0.00144	CbGpPWpGaD
Ezogabine—KCNQ2—Neuronal System—HRAS—uterine cancer	0.000171	0.00138	CbGpPWpGaD
Ezogabine—KCNQ3—Neuronal System—HRAS—uterine cancer	0.000171	0.00138	CbGpPWpGaD
Ezogabine—KCNQ2—Developmental Biology—CTNNB1—uterine cancer	0.00017	0.00137	CbGpPWpGaD
Ezogabine—KCNQ3—Developmental Biology—CTNNB1—uterine cancer	0.00017	0.00137	CbGpPWpGaD
Ezogabine—UGT1A4—Metabolism—AKR1C1—uterine cancer	0.00017	0.00137	CbGpPWpGaD
Ezogabine—UGT1A9—Metabolism of lipids and lipoproteins—AKR1C3—uterine cancer	0.000169	0.00136	CbGpPWpGaD
Ezogabine—NAT2—Metabolism—CYP19A1—uterine cancer	0.000168	0.00135	CbGpPWpGaD
Ezogabine—NAT2—Metabolism—STK11—uterine cancer	0.000168	0.00135	CbGpPWpGaD
Ezogabine—KCNQ3—Developmental Biology—EP300—uterine cancer	0.000158	0.00127	CbGpPWpGaD
Ezogabine—KCNQ2—Developmental Biology—EP300—uterine cancer	0.000158	0.00127	CbGpPWpGaD
Ezogabine—KCNQ3—Axon guidance—HRAS—uterine cancer	0.000152	0.00122	CbGpPWpGaD
Ezogabine—KCNQ2—Axon guidance—HRAS—uterine cancer	0.000152	0.00122	CbGpPWpGaD
Ezogabine—UGT1A4—Metabolism—RRM2—uterine cancer	0.000151	0.00122	CbGpPWpGaD
Ezogabine—UGT1A3—Metabolism—POLD1—uterine cancer	0.000151	0.00121	CbGpPWpGaD
Ezogabine—KCNQ2—Developmental Biology—VEGFA—uterine cancer	0.00015	0.00121	CbGpPWpGaD
Ezogabine—KCNQ3—Developmental Biology—VEGFA—uterine cancer	0.00015	0.00121	CbGpPWpGaD
Ezogabine—KCNQ2—Developmental Biology—NRAS—uterine cancer	0.000148	0.00119	CbGpPWpGaD
Ezogabine—KCNQ3—Developmental Biology—NRAS—uterine cancer	0.000148	0.00119	CbGpPWpGaD
Ezogabine—UGT1A4—Metabolism—DCN—uterine cancer	0.000147	0.00118	CbGpPWpGaD
Ezogabine—CYP2A6—Metabolism—SRD5A2—uterine cancer	0.000142	0.00114	CbGpPWpGaD
Ezogabine—CYP2A6—Metabolism—NDUFB11—uterine cancer	0.000142	0.00114	CbGpPWpGaD
Ezogabine—UGT1A3—Metabolism—AKR1C1—uterine cancer	0.000141	0.00114	CbGpPWpGaD
Ezogabine—UGT1A4—Metabolism—CYP11A1—uterine cancer	0.000138	0.00111	CbGpPWpGaD
Ezogabine—UGT1A1—Metabolism—STAR—uterine cancer	0.000133	0.00107	CbGpPWpGaD
Ezogabine—UGT1A9—Metabolism—AKR1B1—uterine cancer	0.000133	0.00107	CbGpPWpGaD
Ezogabine—UGT1A1—Metabolism—AKR1B1—uterine cancer	0.000133	0.00107	CbGpPWpGaD
Ezogabine—UGT1A9—Metabolism—STAR—uterine cancer	0.000133	0.00107	CbGpPWpGaD
Ezogabine—UGT1A9—Fatty acid, triacylglycerol, and ketone body metabolism—EP300—uterine cancer	0.000132	0.00106	CbGpPWpGaD
Ezogabine—UGT1A9—Metabolism of lipids and lipoproteins—CYP19A1—uterine cancer	0.000131	0.00106	CbGpPWpGaD
Ezogabine—UGT1A4—Metabolism—AKR1C3—uterine cancer	0.000131	0.00105	CbGpPWpGaD
Ezogabine—KCNQ3—Developmental Biology—KRAS—uterine cancer	0.000128	0.00103	CbGpPWpGaD
Ezogabine—KCNQ2—Developmental Biology—KRAS—uterine cancer	0.000128	0.00103	CbGpPWpGaD
Ezogabine—NAT2—Metabolism—MTHFR—uterine cancer	0.000126	0.00102	CbGpPWpGaD
Ezogabine—UGT1A3—Metabolism—RRM2—uterine cancer	0.000126	0.00101	CbGpPWpGaD
Ezogabine—UGT1A3—Metabolism—DCN—uterine cancer	0.000122	0.000982	CbGpPWpGaD
Ezogabine—UGT1A3—Metabolism—CYP11A1—uterine cancer	0.000115	0.000925	CbGpPWpGaD
Ezogabine—UGT1A3—Metabolism—AKR1C3—uterine cancer	0.000109	0.000874	CbGpPWpGaD
Ezogabine—KCNQ2—Developmental Biology—HRAS—uterine cancer	0.000108	0.000872	CbGpPWpGaD
Ezogabine—KCNQ3—Developmental Biology—HRAS—uterine cancer	0.000108	0.000872	CbGpPWpGaD
Ezogabine—UGT1A1—Metabolism—POLD1—uterine cancer	0.000104	0.000838	CbGpPWpGaD
Ezogabine—UGT1A9—Metabolism—POLD1—uterine cancer	0.000104	0.000838	CbGpPWpGaD
Ezogabine—CYP2A6—Metabolism—STAR—uterine cancer	0.000102	0.000824	CbGpPWpGaD
Ezogabine—CYP2A6—Metabolism—AKR1B1—uterine cancer	0.000102	0.000824	CbGpPWpGaD
Ezogabine—UGT1A4—Metabolism—STK11—uterine cancer	0.000102	0.000819	CbGpPWpGaD
Ezogabine—UGT1A4—Metabolism—CYP19A1—uterine cancer	0.000102	0.000819	CbGpPWpGaD
Ezogabine—UGT1A9—Metabolism—AKR1C1—uterine cancer	9.76e-05	0.000784	CbGpPWpGaD
Ezogabine—UGT1A1—Metabolism—AKR1C1—uterine cancer	9.76e-05	0.000784	CbGpPWpGaD
Ezogabine—KCNQ2—Developmental Biology—AKT1—uterine cancer	9.58e-05	0.00077	CbGpPWpGaD
Ezogabine—KCNQ3—Developmental Biology—AKT1—uterine cancer	9.58e-05	0.00077	CbGpPWpGaD
Ezogabine—UGT1A1—Metabolism—RRM2—uterine cancer	8.7e-05	0.000699	CbGpPWpGaD
Ezogabine—UGT1A9—Metabolism—RRM2—uterine cancer	8.7e-05	0.000699	CbGpPWpGaD
Ezogabine—UGT1A3—Metabolism—STK11—uterine cancer	8.47e-05	0.000681	CbGpPWpGaD
Ezogabine—UGT1A3—Metabolism—CYP19A1—uterine cancer	8.47e-05	0.000681	CbGpPWpGaD
Ezogabine—UGT1A1—Metabolism—DCN—uterine cancer	8.44e-05	0.000679	CbGpPWpGaD
Ezogabine—UGT1A9—Metabolism—DCN—uterine cancer	8.44e-05	0.000679	CbGpPWpGaD
Ezogabine—CYP2A6—Metabolism—POLD1—uterine cancer	8.04e-05	0.000646	CbGpPWpGaD
Ezogabine—UGT1A9—Metabolism—CYP11A1—uterine cancer	7.95e-05	0.000639	CbGpPWpGaD
Ezogabine—UGT1A1—Metabolism—CYP11A1—uterine cancer	7.95e-05	0.000639	CbGpPWpGaD
Ezogabine—UGT1A4—Metabolism—MTHFR—uterine cancer	7.66e-05	0.000615	CbGpPWpGaD
Ezogabine—CYP2A6—Metabolism—AKR1C1—uterine cancer	7.52e-05	0.000605	CbGpPWpGaD
Ezogabine—UGT1A1—Metabolism—AKR1C3—uterine cancer	7.51e-05	0.000604	CbGpPWpGaD
Ezogabine—UGT1A9—Metabolism—AKR1C3—uterine cancer	7.51e-05	0.000604	CbGpPWpGaD
Ezogabine—NAT2—Metabolism—PTEN—uterine cancer	7.03e-05	0.000565	CbGpPWpGaD
Ezogabine—NAT2—Metabolism—EP300—uterine cancer	6.7e-05	0.000539	CbGpPWpGaD
Ezogabine—CYP2A6—Metabolism—RRM2—uterine cancer	6.7e-05	0.000539	CbGpPWpGaD
Ezogabine—CYP2A6—Metabolism—DCN—uterine cancer	6.51e-05	0.000523	CbGpPWpGaD
Ezogabine—UGT1A3—Metabolism—MTHFR—uterine cancer	6.36e-05	0.000512	CbGpPWpGaD
Ezogabine—CYP2A6—Metabolism—CYP11A1—uterine cancer	6.13e-05	0.000493	CbGpPWpGaD
Ezogabine—UGT1A9—Metabolism—STK11—uterine cancer	5.85e-05	0.00047	CbGpPWpGaD
Ezogabine—UGT1A1—Metabolism—CYP19A1—uterine cancer	5.85e-05	0.00047	CbGpPWpGaD
Ezogabine—UGT1A9—Metabolism—CYP19A1—uterine cancer	5.85e-05	0.00047	CbGpPWpGaD
Ezogabine—UGT1A1—Metabolism—STK11—uterine cancer	5.85e-05	0.00047	CbGpPWpGaD
Ezogabine—CYP2A6—Metabolism—AKR1C3—uterine cancer	5.79e-05	0.000465	CbGpPWpGaD
Ezogabine—UGT1A9—Metabolism of lipids and lipoproteins—PTEN—uterine cancer	5.49e-05	0.000442	CbGpPWpGaD
Ezogabine—UGT1A9—Metabolism of lipids and lipoproteins—EP300—uterine cancer	5.24e-05	0.000421	CbGpPWpGaD
Ezogabine—NAT2—Metabolism—PIK3CA—uterine cancer	4.96e-05	0.000399	CbGpPWpGaD
Ezogabine—CYP2A6—Metabolism—STK11—uterine cancer	4.51e-05	0.000363	CbGpPWpGaD
Ezogabine—CYP2A6—Metabolism—CYP19A1—uterine cancer	4.51e-05	0.000363	CbGpPWpGaD
Ezogabine—UGT1A1—Metabolism—MTHFR—uterine cancer	4.4e-05	0.000353	CbGpPWpGaD
Ezogabine—UGT1A9—Metabolism—MTHFR—uterine cancer	4.4e-05	0.000353	CbGpPWpGaD
Ezogabine—UGT1A4—Metabolism—PTEN—uterine cancer	4.26e-05	0.000342	CbGpPWpGaD
Ezogabine—UGT1A4—Metabolism—EP300—uterine cancer	4.06e-05	0.000326	CbGpPWpGaD
Ezogabine—NAT2—Metabolism—AKT1—uterine cancer	4.05e-05	0.000326	CbGpPWpGaD
Ezogabine—UGT1A9—Metabolism of lipids and lipoproteins—PIK3CA—uterine cancer	3.87e-05	0.000311	CbGpPWpGaD
Ezogabine—UGT1A3—Metabolism—PTEN—uterine cancer	3.54e-05	0.000285	CbGpPWpGaD
Ezogabine—CYP2A6—Metabolism—MTHFR—uterine cancer	3.39e-05	0.000272	CbGpPWpGaD
Ezogabine—UGT1A3—Metabolism—EP300—uterine cancer	3.38e-05	0.000271	CbGpPWpGaD
Ezogabine—UGT1A4—Metabolism—PIK3CA—uterine cancer	3e-05	0.000242	CbGpPWpGaD
Ezogabine—UGT1A3—Metabolism—PIK3CA—uterine cancer	2.5e-05	0.000201	CbGpPWpGaD
Ezogabine—UGT1A4—Metabolism—AKT1—uterine cancer	2.45e-05	0.000197	CbGpPWpGaD
Ezogabine—UGT1A1—Metabolism—PTEN—uterine cancer	2.45e-05	0.000197	CbGpPWpGaD
Ezogabine—UGT1A9—Metabolism—PTEN—uterine cancer	2.45e-05	0.000197	CbGpPWpGaD
Ezogabine—UGT1A9—Metabolism—EP300—uterine cancer	2.33e-05	0.000188	CbGpPWpGaD
Ezogabine—UGT1A1—Metabolism—EP300—uterine cancer	2.33e-05	0.000188	CbGpPWpGaD
Ezogabine—UGT1A3—Metabolism—AKT1—uterine cancer	2.04e-05	0.000164	CbGpPWpGaD
Ezogabine—CYP2A6—Metabolism—PTEN—uterine cancer	1.89e-05	0.000152	CbGpPWpGaD
Ezogabine—CYP2A6—Metabolism—EP300—uterine cancer	1.8e-05	0.000145	CbGpPWpGaD
Ezogabine—UGT1A9—Metabolism—PIK3CA—uterine cancer	1.73e-05	0.000139	CbGpPWpGaD
Ezogabine—UGT1A1—Metabolism—PIK3CA—uterine cancer	1.73e-05	0.000139	CbGpPWpGaD
Ezogabine—UGT1A1—Metabolism—AKT1—uterine cancer	1.41e-05	0.000113	CbGpPWpGaD
Ezogabine—UGT1A9—Metabolism—AKT1—uterine cancer	1.41e-05	0.000113	CbGpPWpGaD
Ezogabine—CYP2A6—Metabolism—PIK3CA—uterine cancer	1.33e-05	0.000107	CbGpPWpGaD
Ezogabine—CYP2A6—Metabolism—AKT1—uterine cancer	1.09e-05	8.74e-05	CbGpPWpGaD
